Evofem Biosciences, Inc.
0.0120+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · EVFM · USD
Key Stats
Market Cap
1.42MP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
8-K
Merger terminated by shareholder vote
Evofem Biosciences terminated its merger agreement with Aditxt on October 20, 2025, after shareholders rejected the deal at a special meeting, with 93.2 million votes for but 7.2 million against among 100.5 million cast. No termination fees were paid, ending ancillary pacts except a 2023 NDA. The company now pivots to regaining national stock listing and raising growth capital to hit positive EBITDA in 2027. Merger fallout risks litigation and partner retention.
8-K
Evofem amends note maturity
Evofem Biosciences amended its securities purchase agreement with Adjuvant funds on October 13, 2025, setting a new six-month maturity for the outstanding convertible promissory notes. This shortens the repayment timeline while prohibiting prepayment without Adjuvant's consent, unless triggered by a change of control or acceleration. The move tightens debt terms. No financial amounts disclosed.
8-K
Evofem swaps notes for preferred
Evofem Biosciences exchanged $1,573,000 in senior secured convertible notes for 1,573 shares of newly created Series G-1 Convertible Preferred Stock on August 22, 2025, reducing immediate debt while granting holders voting rights equivalent to convertible common shares at $0.0154 per share. This move supports the ongoing merger with Aditxt, refined by a sixth amendment on August 26 that updates preferred stock definitions, approval requirements, and limits dissenting shares to 5,932,818 common or 202 preferred. Debt swap eases pressure. Triggering events could force discounted conversions.
8-K
Evofem Q2 sales rise 16%
Evofem Biosciences reported Q2 2025 net sales of $4.8 million, up 16% from $4.2 million last year, driven by SOLOSEC additions and PHEXXI pricing, while narrowing operating loss to $1.3 million from $1.4 million. The company advanced cost reductions targeting 50% manufacturing savings and UAE market entries for both products via Pharma 1 partnerships. Sales rebounded sharply. Yet merger with Aditxt hinges on stockholder approval and $15 million funding, with cash at $0.7 million.
10-Q
Q2 FY2025 results
Evofem Biosciences posted Q2 FY2025 net product sales of $4.8M, up 16% y/y from $4.2M, fueled by SOLOSEC's addition and a January WAC hike, though YTD sales dipped 27% y/y to $5.7M amid softer PHEXXI volumes. Gross margins held steady at 84.4%, with COGS edging down 2% y/y to $0.8M as Rush royalties expired, offset by new SOLOSEC costs; operating loss narrowed to $1.3M from $1.4M y/y, but YTD swung to a $0.9M loss from $4.2M. Diluted EPS came in at -$0.02, matching y/y, with 116M shares; non-GAAP metrics not disclosed in the 10-Q. Cash sat at zero, with $0.7M restricted and $2.4M net from Aditxt notes bolstering liquidity, while $160M debt loomed large. The SOLOSEC acquisition in July 2024 added $4.7M intangible (16-year life) and $5.4M contingent liabilities. Merger talks with Aditxt drag on. Debt defaults pose the sharpest risk.
BSEM
BioStem Technologies, Inc.
4.66+0.16
CASI
CASI Pharmaceuticals, Inc.
1.42-0.14
DARE
Dare Bioscience, Inc.
2.02-0.01
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENVB
Enveric Biosciences, Inc.
6.70-0.42
EPIX
ESSA Pharma Inc.
0.20+0.00
EVGN
Evogene Ltd.
1.28-0.03
EVOK
Evoke Pharma, Inc.
5.12+0.22
FEMY
Femasys Inc.
0.63-0.03
PHGE
BiomX Inc.
0.55-0.03